ClinicalTrials.gg
CompletedNCT00972179Updated Sep 21, 2022Results posted

Safety Study of Tezepelumab (AMG 157) in Healthy Adults

A Phase 1 interventional study of Placebo and Tezepelumab in Healthy Volunteers, sponsored by Amgen. Completed. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-21.

Sponsored by Amgen · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The primary objective is to evaluate the safety, tolerability, and immunogenicity of multiple-dose administration of tezepelumab in healthy adults.

Read the detailed description

This study will follow a randomized, multiple-dose, double-blind, placebo-controlled, sequential dose-escalation study design. The study will consist of five subcutaneous (SC) cohorts and one intravenous (IV) cohort. Each dose cohort is planned to enroll 8 participants, randomized such that 6 participants will receive tezepelumab and 2 will receive placebo (3:1 ratio).

02

Conditions studied

  • Healthy Volunteers

Keywords

  • healthy volunteers
03

In context

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must sign an Institutional Review Board (IRB) approved form before any study-specific procedures;
  • Healthy subject, aged between 18 and 45 years, inclusive;
  • Female subject must be of non- (ie, by history - no menses for ≥ 1 year and by follicle-stimulating hormone (FSH) [using local reference ranges]; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy);
  • Male subjects with female partner of who agrees to inform their female partner of their participation in this clinical study and use highly effective methods of during the study. (Highly effective methods of birth control may include abstinence, vasectomy, or a condom with spermicide in combination with either hormonal birth control, intra-uterine device, or barrier methods used by the woman);
  • Male subject who agrees to use birth control for five months after last dose of study medication, male subject who agrees not to donate sperm during the study and for five months after last dose of study medication;
  • Healthy subject with a (BMI) between 18 and 32 kg/m\^2, inclusive at screening;
  • Subject must have normal or clinically acceptable physical examination and (ECG) results prior to Day 1 based on the opinion of the investigator;
  • Subject must have normal or clinically acceptable clinical laboratory tests at screening as determined by Amgen and the investigator;
  • Subject must have adequate renal function (defined as > 80 mL/min using the Cockcroft Gault equation).

Exclusion criteria

Exclusion Criteria:

  • Subject who has history or evidence of a disorder, condition or disease (including but not limited to cardiopulmonary, oncologic, immunologic, , collagen vascular, renal, metabolic, hematologic or psychiatric), that, in the opinion of the Investigator in consultation with the Amgen physician, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion;
  • Subject who has evidence of any active or suspected bacterial, viral, fungal or parasitic infections within the past 30 days prior to randomization (eg, common cold, viral syndrome, flu-like symptoms). Subject who, in the opinion of the investigator, has a high risk of parasitic disease is also excluded;
  • Subject who has known positive tuberculin skin test (if not treated with appropriate chemoprophylaxis) or recent (within six months from randomization) exposure to an individual with active tuberculosis;
  • Subject who has history of of any type, other than in situ cervical cancer or surgically excised non-melanomatous skin cancers within five years before randomization of the study;
  • Subject who has known type I/II diabetes;
  • Subject who uses nonprescription drugs within 14 days prior to randomization and for the entire duration of the study. All herbal supplements, vitamins, and nutritional supplements taken within the last 30 days prior to dosing on Day 1 (and continued use, if appropriate), must be reviewed and approved by the PI and Amgen Medical Monitor;
  • Subject who has used any systemic cytotoxic or systemic medications (other than ) within 6 months prior to randomization and for the entire duration of the study or has used any corticosteroid, topical cytotoxic or topical immunosuppressive medications within 30 days or five half-lives (whichever is longer) prior to randomization and for the entire duration of the study;
  • Subject who has previously received any other therapeutic monoclonal antibody;
  • Subject who has previously received any drug (or is currently using an investigational device) within 30 days or five half-lives (whichever is longer) prior to randomization;
  • Subject who has tested positive for drugs and/or alcohol use at screening or before randomization, subject who has consumed alcohol within 48 hours prior to any study visit including screening, and subject with alcohol intake of > 2 drinks/day on average during the study (one drink being equivalent to 12 ounces of regular beer, 8 to 9 ounces of malt liquor, 5 ounces of wine or 1.5 ounces of 80 proof distilled spirits);
  • Female subject who is pregnant or lactating; female subject who is of ;
  • Subject who has donated blood (including blood products) or experienced loss of blood ≥ 500 mL within two months of study screening;
  • Subject who is positive for (HIV) antibodies, surface antigen, or antibodies;
  • Subject who has regularly used nicotine or tobacco containing products (including but not limited to: snuff, chewing tobacco, cigars, cigarettes, pipes, or nicotine patches) during six months before randomization and during the study;
  • Subject who has any other condition that might reduce the chance of obtaining data (eg, known poor compliance) required by the protocol or that might compromise the ability to give truly .
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Tezepelumab

    Tezepelumab will be administered subcutaneously (SC) at doses from 35 mg once every 28 days (Q28D) (cohort 1) up to 210 mg once every 7 days (Q7D) (cohort 5) and an intravenous (IV) dose cohort of 700 mg Q28D (cohort 6).

    Drug: Tezepelumab

  • Placebo comparator
    Placebo

    Two participants in each cohort (cohorts 1 to 6) will receive matching placebo administered subcutaneously (cohorts 1-5) or intravenously (cohort 6), matching the treatment regiment of tezepelumab.

    Drug: Placebo

Interventions

  • DrugPlacebo

    Administered by subcutaneous or intravenous injection.

  • Administered by subcutaneous or intravenous injection

    Also known as: AMG 157, Tezspire

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events

    Adverse events (AEs) include any untoward medical occurrence in a trial participant administered a study drug and does not necessarily have a causal relationship with this treatment. AEs include worsening of a pre-existing medical condition and laboratory value changes requiring therapy or adjustment in prior therapy. AEs were assessed for severity according to the Common Terminology Criteria for Adverse Events (CTCAE), Version 3, where Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = severe AE, Grade 4 = life-threatening AE and Grade 5 = death due to AE. Relationship to study treatment was determined by the investigator. A serious adverse event (SAE) is defined as an AE that met 1 or more of below criteria: * was fatal; * was life threatening; * required in-patient hospitalization or prolongation of existing hospitalization; * resulted in persistent or significant disability/incapacity; * was a congenital anomaly/birth defect; * other significant medical hazard.

    Time frame: From first dose of study drug up to day 169

  2. Number of Participants Who Developed Anti-tezepelumab Antibodies After Initiation of Treatment

    All study samples (tezepelumab and placebo) were tested using an electrochemiluminescence (ECL) based immunoassay to detect and confirm the presence of antibodies capable of binding to tezepelumab. Samples identified as positive in the immunoassay were tested in a receptor-binding ECL-based assay to detect neutralizing or inhibitory effects toward tezepelumab. The number of participants with positive anti-tezepelumab binding antibodies / neutralizing antibodies at any time post-baseline with a negative or no result at baseline is reported.

    Time frame: For Q28D groups: Days 28, 56, 85, 113, and 169; For Q14D and Q7D groups: Days 29, 57, 85, 113, 141, and 169

Secondary outcomes

  1. Time of Maximum Observed Concentration (Tmax) of Tezepelumab

    The pharmacokinetic (PK) parameter Tmax was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification of the assay was 10 ng/ml.

    Time frame: First dose: Day 1 predose, end of infusion (EOI; IV cohort only), 4 hours, 3, 7, 14 (Q14D & Q28D only) and 28 days (Q28D only) postdose. Last Dose: Day 57 (Q28D), Day 71 (Q14D) and Day 78 (Q7D) predose, EOI (IV cohort), 4 hours, 3, 7, 14, 28 days postdose

  2. Maximum Observed Concentration (Cmax) of Tezepelumab

    The PK parameter Cmax was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/ml.

    Time frame: First dose: Day 1 predose, end of infusion (EOI; IV cohort only), 4 hours, 3, 7, 14 (Q14D & Q28D only) and 28 days (Q28D only) postdose. Last Dose: Day 57 (Q28D), Day 71 (Q14D) and Day 78 (Q7D) predose, EOI (IV cohort), 4 hours, 3, 7, 14, 28 days postdose

  3. Area Under the Concentration-time Curve Over the Dosing Interval (AUCtau) for Tezepelumab

    The PK parameter AUCtau was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The dosing interval (tau) was 28 days, 14 days or 7 days depending on the treatment arm. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/ml.

    Time frame: First dose: Day 1 predose, end of infusion (EOI; IV cohort only), 4 hours, 3, 7, 14 (Q14D & Q28D only) and 28 days (Q28D only) postdose. Last Dose: Day 57 (Q28D), Day 71 (Q14D) and Day 78 (Q7D) predose, EOI (IV cohort), 4 hours, 3, 7, 14, 28 days postdose

  4. Accumulation Ratio Based on AUCtau

    Accumulation ratio (AR) based on AUCtau was calculated as AUCtau after last dose / AUCtau after first dose, except for the Q7D cohort where AR was calculated as AUCtau after last dose / area under the concentration-time curve from time 0 to time of last measurable concentration (AUC0-t) after first dose.

    Time frame: First dose: Day 1 predose, end of infusion (EOI; IV cohort only), 4 hours, 3, 7, 14 (Q14D & Q28D only) and 28 days (Q28D only) postdose. Last Dose: Day 57 (Q28D), Day 71 (Q14D) and Day 78 (Q7D) predose, EOI (IV cohort), 4 hours, 3, 7, 14, 28 days postdose

  5. Accumulation Ratio Based on Cmax

    Accumulation ratio based on Cmax calculated as Cmax after last dose / Cmax after first dose

    Time frame: First dose: Day 1 predose, end of infusion (EOI; IV cohort only), 4 hours, 3, 7, 14 (Q14D & Q28D only) and 28 days (Q28D only) postdose. Last Dose: Day 57 (Q28D), Day 71 (Q14D) and Day 78 (Q7D) predose, EOI (IV cohort), 4 hours, 3, 7, 14, 28 days postdose

07

Results

Posted May 23, 2022

Participant flow

This study was conducted at a single center in the United States.

Participant flow — Overall Study
MilestoneTezepelumab 35 mg Q28DTezepelumab 105 mg Q28DTezepelumab 210 mg Q28DTezepelumab 210 mg Q14DTezepelumab 210 mg Q7DTezepelumab 700 mg Q28D IVPlacebo
Started66667612
Completed5355538
Not completed1311234
Withdrew: Noncompliance1000101
Withdrew: Withdrawal by subject0301002
Withdrew: Administrative decision0000100
Withdrew: Lost to follow-up0010031

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events

Adverse events (AEs) include any untoward medical occurrence in a trial participant administered a study drug and does not necessarily have a causal relationship with this treatment. AEs include worsening of a pre-existing medical condition and laboratory value changes requiring therapy or adjustment in prior therapy. AEs were assessed for severity according to the Common Terminology Criteria for Adverse Events (CTCAE), Version 3, where Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = severe AE, Grade 4 = life-threatening AE and Grade 5 = death due to AE. Relationship to study treatment was determined by the investigator. A serious adverse event (SAE) is defined as an AE that met 1 or more of below criteria: * was fatal; * was life threatening; * required in-patient hospitalization or prolongation of existing hospitalization; * resulted in persistent or significant disability/incapacity; * was a congenital anomaly/birth defect; * other significant medical hazard.

Time frame:
From first dose of study drug up to day 169
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events
ParticipantsTezepelumab 35 mg Q28DTezepelumab 105 mg Q28DTezepelumab 210 mg Q28DTezepelumab 210 mg Q14DTezepelumab 210 mg Q7DTezepelumab 700 mg Q28D IVPlacebo
Any adverse event44265310
Serious adverse events1000000
AE Leading to discontinuation of study drug0000000
AE Leading to discontinuation from study0000000
Grade 3 adverse events1001112
Grade 4 adverse events0000100
Fatal (grade 5) adverse events0000000
Any treatment-related adverse event2011302
SecondaryTime of Maximum Observed Concentration (Tmax) of Tezepelumab

The pharmacokinetic (PK) parameter Tmax was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated enzyme-linked immunosorbent assay (ELISA). The lower limit of quantification of the assay was 10 ng/ml.

Time frame:
First dose: Day 1 predose, end of infusion (EOI; IV cohort only), 4 hours, 3, 7, 14 (Q14D & Q28D only) and 28 days (Q28D only) postdose. Last Dose: Day 57 (Q28D), Day 71 (Q14D) and Day 78 (Q7D) predose, EOI (IV cohort), 4 hours, 3, 7, 14, 28 days postdose
Reported as:
Median · hours
Time of Maximum Observed Concentration (Tmax) of Tezepelumab
hoursTezepelumab 35 mg Q28DTezepelumab 105 mg Q28DTezepelumab 210 mg Q28DTezepelumab 210 mg Q14DTezepelumab 210 mg Q7DTezepelumab 700 mg Q28D IV
First dose160 (69.7 to 167)71.5 (70.4 to 167)118 (68.7 to 166)70.7 (69.9 to 168)164 (66.9 to 165)4.00 (1.13 to 4.17)
Last dose166 (68.6 to 176)71.8 (70.7 to 167)167 (69.3 to 168)66.5 (65.1 to 162)74.4 (65.9 to 164)3.97 (1.17 to 4.03)
PrimaryNumber of Participants Who Developed Anti-tezepelumab Antibodies After Initiation of Treatment

All study samples (tezepelumab and placebo) were tested using an electrochemiluminescence (ECL) based immunoassay to detect and confirm the presence of antibodies capable of binding to tezepelumab. Samples identified as positive in the immunoassay were tested in a receptor-binding ECL-based assay to detect neutralizing or inhibitory effects toward tezepelumab. The number of participants with positive anti-tezepelumab binding antibodies / neutralizing antibodies at any time post-baseline with a negative or no result at baseline is reported.

Time frame:
For Q28D groups: Days 28, 56, 85, 113, and 169; For Q14D and Q7D groups: Days 29, 57, 85, 113, 141, and 169
Reported as:
Count of participants · Participants
Number of Participants Who Developed Anti-tezepelumab Antibodies After Initiation of Treatment
ParticipantsTezepelumab 35 mg Q28DTezepelumab 105 mg Q28DTezepelumab 210 mg Q28DTezepelumab 210 mg Q14DTezepelumab 210 mg Q7DTezepelumab 700 mg Q28D IVPlacebo
Anti-tezepelumab binding antibodies0000000
Anti-tezepelumab neutralizing antibodies0000000
SecondaryMaximum Observed Concentration (Cmax) of Tezepelumab

The PK parameter Cmax was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/ml.

Time frame:
First dose: Day 1 predose, end of infusion (EOI; IV cohort only), 4 hours, 3, 7, 14 (Q14D & Q28D only) and 28 days (Q28D only) postdose. Last Dose: Day 57 (Q28D), Day 71 (Q14D) and Day 78 (Q7D) predose, EOI (IV cohort), 4 hours, 3, 7, 14, 28 days postdose
Reported as:
Mean · µg/mL
Maximum Observed Concentration (Cmax) of Tezepelumab
µg/mLTezepelumab 35 mg Q28DTezepelumab 105 mg Q28DTezepelumab 210 mg Q28DTezepelumab 210 mg Q14DTezepelumab 210 mg Q7DTezepelumab 700 mg Q28D IV
First dose3.70 ± 1.1610.7 ± 3.1323.6 ± 9.5023.8 ± 5.4018.0 ± 4.58294 ± 48.2
Last dose6.29 ± 2.0216.6 ± 2.0237.4 ± 17.563.8 ± 13.5117 ± 45.6370 ± 74.9
SecondaryArea Under the Concentration-time Curve Over the Dosing Interval (AUCtau) for Tezepelumab

The PK parameter AUCtau was estimated based on the serum concentrations of tezepelumab using noncompartmental methods. The dosing interval (tau) was 28 days, 14 days or 7 days depending on the treatment arm. The concentration of tezepelumab in human serum was measured using a validated ELISA. The lower limit of quantification of the assay was 10 ng/ml.

Time frame:
First dose: Day 1 predose, end of infusion (EOI; IV cohort only), 4 hours, 3, 7, 14 (Q14D & Q28D only) and 28 days (Q28D only) postdose. Last Dose: Day 57 (Q28D), Day 71 (Q14D) and Day 78 (Q7D) predose, EOI (IV cohort), 4 hours, 3, 7, 14, 28 days postdose
Reported as:
Mean · days*µg/mL
Area Under the Concentration-time Curve Over the Dosing Interval (AUCtau) for Tezepelumab
days*µg/mLTezepelumab 35 mg Q28DTezepelumab 105 mg Q28DTezepelumab 210 mg Q28DTezepelumab 210 mg Q14DTezepelumab 210 mg Q7DTezepelumab 700 mg Q28D IV
First dose78.9 ± 23.4237 ± 50.5481 ± 171263 ± 49.284.3 ± 34.92980 ± 395
Last dose136 ± 35.9333 ± 28.8799 ± 338787 ± 180732 ± 2244050 ± 1270
SecondaryAccumulation Ratio Based on AUCtau

Accumulation ratio (AR) based on AUCtau was calculated as AUCtau after last dose / AUCtau after first dose, except for the Q7D cohort where AR was calculated as AUCtau after last dose / area under the concentration-time curve from time 0 to time of last measurable concentration (AUC0-t) after first dose.

Time frame:
First dose: Day 1 predose, end of infusion (EOI; IV cohort only), 4 hours, 3, 7, 14 (Q14D & Q28D only) and 28 days (Q28D only) postdose. Last Dose: Day 57 (Q28D), Day 71 (Q14D) and Day 78 (Q7D) predose, EOI (IV cohort), 4 hours, 3, 7, 14, 28 days postdose
Reported as:
Mean · ratio
Accumulation Ratio Based on AUCtau
ratioTezepelumab 35 mg Q28DTezepelumab 105 mg Q28DTezepelumab 210 mg Q28DTezepelumab 210 mg Q14DTezepelumab 210 mg Q7DTezepelumab 700 mg Q28D IV
Accumulation Ratio Based on AUCtau1.82 ± 0.2621.64 ± 0.08831.59 ± 0.2422.89 ± 0.8928.23 ± 1.931.34 ± 0.314
SecondaryAccumulation Ratio Based on Cmax

Accumulation ratio based on Cmax calculated as Cmax after last dose / Cmax after first dose

Time frame:
First dose: Day 1 predose, end of infusion (EOI; IV cohort only), 4 hours, 3, 7, 14 (Q14D & Q28D only) and 28 days (Q28D only) postdose. Last Dose: Day 57 (Q28D), Day 71 (Q14D) and Day 78 (Q7D) predose, EOI (IV cohort), 4 hours, 3, 7, 14, 28 days postdose
Reported as:
Mean · ratio
Accumulation Ratio Based on Cmax
ratioTezepelumab 35 mg Q28DTezepelumab 105 mg Q28DTezepelumab 210 mg Q28DTezepelumab 210 mg Q14DTezepelumab 210 mg Q7DTezepelumab 700 mg Q28D IV
Accumulation Ratio Based on Cmax1.79 ± 0.3921.66 ± 0.09011.59 ± 0.2882.84 ± 0.9656.74 ± 1.691.30 ± 0.176

Adverse events

Collected over From first dose of study drug up to day 169. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tezepelumab 35 mg Q28D—1/6 (16.7%)4/6 (66.7%)
Tezepelumab 105 mg Q28D—0/6 (0%)4/6 (66.7%)
Tezepelumab 210 mg Q28D—0/6 (0%)2/6 (33.3%)
Tezepelumab 210 mg Q14D—0/6 (0%)6/6 (100%)
Tezepelumab 210 mg Q7D—0/7 (0%)5/7 (71.4%)
Tezepelumab 700 mg Q28D IV—0/6 (0%)3/6 (50%)
Tezepelumab Total—1/37 (2.7%)24/37 (64.9%)
Placebo—0/12 (0%)10/12 (83.3%)
Most frequent serious events
Most frequent serious events
EventTezepelumab 35 mg Q28DTezepelumab 105 mg Q28DTezepelumab 210 mg Q28DTezepelumab 210 mg Q14DTezepelumab 210 mg Q7DTezepelumab 700 mg Q28D IVTezepelumab TotalPlacebo
Hepatitis CInfections and infestations1/60/60/60/60/70/61/370/12
Most frequent other events
Showing 10 of 51
Most frequent other events
EventTezepelumab 35 mg Q28DTezepelumab 105 mg Q28DTezepelumab 210 mg Q28DTezepelumab 210 mg Q14DTezepelumab 210 mg Q7DTezepelumab 700 mg Q28D IVTezepelumab TotalPlacebo
HeadacheNervous system disorders0/62/61/62/63/70/68/372/12
PruritusSkin and subcutaneous tissue disorders2/60/60/60/61/70/63/370/12
Injection site haematomaGeneral disorders0/60/60/60/62/70/62/371/12
Injection site painGeneral disorders0/60/61/60/62/70/63/370/12
Blood creatine phosphokinase increasedInvestigations0/60/60/60/62/71/63/372/12
Eye irritationEye disorders0/60/60/61/60/70/61/370/12
Abdominal painGastrointestinal disorders0/60/61/60/60/70/61/370/12
NauseaGastrointestinal disorders0/60/60/61/61/70/62/370/12
Application site dermatitisGeneral disorders0/61/60/61/60/70/62/370/12
FatigueGeneral disorders0/60/60/61/61/70/62/371/12

Baseline characteristics

Participants who received at least 1 dose of study drug (Safety population).

Age, Continuous
Age, Continuous(year)Tezepelumab 35 mg Q28DTezepelumab 105 mg Q28DTezepelumab 210 mg Q28DTezepelumab 210 mg Q14DTezepelumab 210 mg Q7DTezepelumab 700 mg Q28D IVPlaceboTotal
Mean29.8 ± 9.334.8 ± 5.832.3 ± 5.331.5 ± 5.636.1 ± 7.727.7 ± 4.134.1 ± 5.232.6 ± 6.4
Sex: Female, Male
Sex: Female, Male(Participants)Tezepelumab 35 mg Q28DTezepelumab 105 mg Q28DTezepelumab 210 mg Q28DTezepelumab 210 mg Q14DTezepelumab 210 mg Q7DTezepelumab 700 mg Q28D IVPlaceboTotal
Female00041027
Male6662661042
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tezepelumab 35 mg Q28DTezepelumab 105 mg Q28DTezepelumab 210 mg Q28DTezepelumab 210 mg Q14DTezepelumab 210 mg Q7DTezepelumab 700 mg Q28D IVPlaceboTotal
White302143417
Black or African American00000213
Hispanic or Latino364531729
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Parnes JR, Sullivan JT, Chen L, Dias C. Pharmacokinetics, Safety, and Tolerability of Tezepelumab (AMG 157) in Healthy and Atopic Dermatitis Adult Subjects. Clin Pharmacol Ther. 2019 Aug;106(2):441-449. doi: 10.1002/cpt.1401. Epub 2019 Mar 23. PubMed 30779339 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2009 to primary completion in Jan 2011, 15 months.

Results were first posted in May 2022, 11 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2009
First posted
Sep 4, 2009
StartActual
Sep 15, 2009
Primary completionActual
Jan 9, 2011
CompletionActual
Jan 9, 2011
Results first posted
May 23, 2022
Last update
Sep 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00972179
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Sep 4, 2009
Start date
Sep 15, 2009
Primary completion
Jan 9, 2011
Completion
Jan 9, 2011
Results posted
May 23, 2022
Last update
Sep 21, 2022

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tezepelumab

Start the discussion